Sygnia lists new Healthcare ETF on A2X
The Sygnia Itrix Solactive Healthcare 150 exchange traded fund (ETF) has been approved for a secondary listing on A2X Markets.
Sygnia’s newest ETF listed on the Johannesburg Stock Exchange (JSE) on Friday, 6 August and will be available for trade on A2X from 17 August 2021, joining twelve other Sygnia Itrix ETFs on A2X.
The Sygnia Itrix Solactive Healthcare 150 ETF is a high risk, passively managed index- tracking fund whose objective is to replicate the price and yield performance of the Solactive Developed Markets Healthcare 150 Index.
Sygnia is the largest international equity ETF provider in South Africa, offering investors the widest range of ETFs that track international equity markets.
Sygnia CEO David Hufton said, “The healthcare sector has never been more relevant than it is right now. By listing this ETF on A2X, our local investors not only have exposure to international companies at the forefront of scientific innovation and healthcare, they are also able to extract additional benefits and save money through A2X’s low-cost platform when they transact.”
Kevin Brady, A2X CEO, said, “We are delighted to list the latest Sygnia ETF on our platform. We look forward to demonstrating all the benefits a listing on A2X has to offer Sygnia investors, including lower exchange fees, narrower spreads and added liquidity.”
The listing of this ETF brings the number of instruments available for trade on A2X to 54, with a combined market capitalisation of over R4 trillion. A2X was authorised by its dual regulators, the FSCA and the Prudential Authority, to secondary list exchange traded products in 2019 and will now offer 16 ETFs and 2 ETNs on its market.
A2X is a licensed stock exchange that provides a secondary listing venue for companies. It is regulated by the Financial Sector Conduct Authority and the Prudential Authority (SARB) in terms of the Financial Markets Act. A2X began trading in October 2017 and has seven approved brokers that account for over 60% of total market activity.
